A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion (ECOG 1208)

Conditions

Liver | Liver Cancer

What is the purpose of this trial?

To compare Progression-Free Survival (PFS) of chemoembolization alone to sorafenib in combination with chemoembolization.


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Dates:
04/07/2011
Last Updated:
Study HIC#:
1102008042